Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2020-04-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于分拆所属子公司上市的一般风险提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the proposed spin-off and listing of its subsidiary on the Growth Enterprise Market (创业板). It includes risk warnings related to the spin-off, mentions board approval, and regulatory procedures. The document is short (697 characters) and serves as a risk notification and update on a corporate action rather than a detailed financial report or formal filing like an M&A or capital update. It does not contain financial statements or detailed transaction data. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a corporate event and associated risks, without detailed financial or transaction data.
2020-04-20 Chinese
2019年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2019 annual equity distribution plan by 华兰生物工程股份有限公司. It details the dividend payment per share, the stock dividend (capitalization of reserves), the record date, ex-dividend date, and the method of distribution. It also includes information on shareholding changes post-distribution and tax notes related to dividends. The document is relatively short (2187 characters) and focuses on the dividend distribution details rather than presenting a full financial report or earnings data. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2020-04-20 Chinese
第七届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 9th meeting of the 7th Board of Directors of 华兰生物工程股份有限公司. It includes multiple board decisions related to the proposed spin-off and listing of a subsidiary (华兰疫苗) on the Shenzhen Stock Exchange's ChiNext board. The document discusses compliance with relevant laws and regulations, financial audit reports, independence and governance matters, and authorizations for the spin-off process. It also includes changes to board committee members and a guarantee for a subsidiary's loan. The content is focused on board meeting resolutions and management decisions rather than a full financial report, earnings release, or investor presentation. It is not a proxy solicitation or voting results announcement, but a formal board/management information disclosure. The document length is over 10,000 characters and contains substantive content about board decisions and management information. Therefore, the most appropriate classification is Board/Management Information (MANG).
2020-04-20 Chinese
2019年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and proceedings of the 2019 Annual General Meeting (AGM) of 华兰生物工程股份有限公司. It details the legality of the meeting's convening, the qualifications of attendees, the proposals submitted, and the voting results on various agenda items including the 2019 annual report, financial statements, profit distribution, appointment of auditors, and changes in independent directors. The document does not contain the actual annual report or financial statements but rather confirms the legality and validity of the AGM and its resolutions. The document length is 4317 characters, which is relatively short and consistent with a legal opinion or meeting summary rather than a full report. Therefore, this document is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of the AGM proposals.
2020-04-15 Chinese
2019年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a 2019 Annual General Meeting (AGM) resolution announcement for 华兰生物工程股份有限公司. It details the date and method of the meeting, attendance, voting results on various proposals including the 2019 annual reports, financial statements, profit distribution, appointment of auditors, and changes in independent directors. The document includes voting percentages and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but reports the official results of shareholder votes at the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA).
2020-04-15 Chinese
关于部分高管减持股份计划期限届满并继续减持的预披露公告
Director's Dealing Classification · 100% confidence The document is a detailed announcement regarding the share reduction plans and actual share sales by several senior executives of the company. It includes specific data on share quantities, prices, dates, and compliance with relevant securities laws and regulations. The content focuses on insider share transactions by company directors and senior management, including their commitments and legal compliance. There is no indication of financial results, audit information, or general regulatory announcements unrelated to insider dealings. The document matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length and detail confirm it is the report itself, not just an announcement of a report.
2020-04-12 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.